晚期ALK重排非小细胞肺癌伴或不伴基线脑转移的放疗最佳时机与临床价值:来自失败模式分析的启示
该回顾性研究纳入93例连续接受克唑替尼治疗的ALK阳性非小细胞肺癌患者,中位随访22.0个月,52例治疗失败。脑是最常见首发进展部位,伴基线脑转移者更易出现脑内多发病灶进展(p=0.002)。克唑替尼前脑放疗可改变失败模式并改善PFS1(p=0.006),解救放疗显著延长PFS2(p=0.003),任何放疗与更长总生存相关(p=0.048)。
要点
- 脑是克唑替尼治疗失败时最常见的首发进展部位。
- 伴基线脑转移者脑内多发病灶进展风险显著更高(p=0.002)。
- 克唑替尼前脑放疗可改变失败模式并改善PFS1(p=0.006)。
核心结论
- 对于基线寡转移脑病灶且适合立体定向放射外科的患者, upfront脑放疗提供相当临床获益。
- 对于无症状多转移病灶患者,颅外放疗可推迟。
研究设计与样本
- 回顾性纳入连续接受克唑替尼治疗、影像充分且病灶可测量的非小细胞肺癌患者,共93例。
- 中位随访22.0个月(范围2.0-72.0个月)。
- 原部位进展定义为原发或转移灶进展,新部位进展为远处失败,两者兼有为ODF;PFS1为克唑替尼开始至首次进展,PFS2为首次进展至第二次进展。
主要发现
- 52例患者克唑替尼治疗失败,OF、ODF和DF频率分别为50.0%、26.9%和23.1%。
- 组织学、原发肿瘤大小和基线脑转移存在与OF独立相关(竞争风险分析)。
- 伴基线脑转移者发生脑内多发病灶进展的可能性显著更高(p=0.002)。
- 10例基线寡转移脑病灶未接受 upfront脑放疗者中4例出现脑内多发病灶进展。
- 克唑替尼前脑放疗可改变疾病失败模式并改善伴基线脑转移者的PFS1(p=0.006)。
临床怎么用
- 对于基线寡转移脑病灶且适合立体定向放射外科的患者,作者认为 upfront脑放疗提供相当临床获益。
- 对于无症状多转移病灶患者,作者认为颅外放疗可推迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.
引用
- Ni J, Li G, Yang X, et al. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses. Radiat Oncol. 2019. PMID: 30866974. doi:10.1186/s13014-019-1240-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。